Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination product is a nutritional supplement formulation containing myo-inositol (2g), L-tyrosine (0.5mg), chromium picolinate (40mcg), selenium (55mcg), and folic acid (0.2mg). It is primarily investigated for the treatment of polycystic ovary syndrome (PCOS), particularly across various phenotypes. The formulation acts as an insulin sensitizer and targets hormonal regulation, including thyroid-stimulating hormone (TSH) and follicle-stimulating hormone (FSH) signaling pathways. Clinical evidence, including studies conducted at Altamedica Reproductive Medicine (NCT03673995), suggests that the synergistic action of these components helps restore menstrual regularity, improve ovulation, and reduce hyperandrogenism and BMI in affected patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on myo-inositol + l-tyrosine + chromium picolinate + selenium + folic acid.